Gain Therapeutics: rexaceract motor scores stable
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Gain Therapeutics, Inc. reported 12-month Phase 1b results for rexaceract: all 13 evaluable participants completed the 12-month administration, including the three-month initial study and nine-month open-label extension. MDS-UPDRS motor scores were stable compared with baseline, with no overall disease progression measured by Parts II and III among those participants.
After 90 days, all 11 evaluable patients with Parkinson’s disease who had evaluable cerebrospinal fluid samples had reduced or unchanged CSF GluSph from baseline. A participant later diagnosed with multiple system atrophy showed a change in GluSph in the opposite direction and no meaningful clinical response. The company said rexaceract was generally well tolerated over 12 months; no new safety concerns arose in Part 2 reviews, Treatment-Emergent Adverse Events had a lower incidence in Part 2 than Part 1, and no new clinically relevant liver enzyme elevations were observed with continued dosing for up to one year.
8-K Event Classification
Key Figures
Key Terms
Phase 1b clinical study medical
MDS-UPDRS Parts II and III scales medical
cerebrospinal fluid (CSF) medical
glucosylsphingosine (GluSph) medical
open-label extension medical
Treatment-Emergent Adverse Events (TEAEs) medical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did GANX report from rexaceract’s 12-month Phase 1b study?
What happened to CSF GluSph in GANX’s rexaceract study?
AI-generated analysis. How Rhea-AI works. Not financial advice.